drugset / Trial / NCT02034578

Phase 1 Oral Solution Bioavailability Study of Apixaban When Administered Through a Nasogastric Tube in Healthy Subjects

NCT02034578

Phase 1 Completed 75 enrolled Bristol-Myers Squibb Pfizer · collab
RandomizedCrossoverOpen-labelBasic science

Summary

The purpose of this study is to assess the bioavailability of Apixaban solution administered through NGT and washed with Dextrose 5% in water (D5W) or infant formula relative to Apixaban solution administered orally in healthy subjects

Timeline

Start
2011-07
Primary completion
2011-08
Completion
2011-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Apixaban Small molecule 5 mg Oral

Indications

No indication recorded.